Orphan Drugs: From Regulatory Issues to Clinical Transition
- ISBN-10
- 1498763073
- ISBN-13
- 9781498763073
- Series
- Orphan Drugs
- Pages
- 320
- Language
- English
- Published
- 2016-12-15
- Publisher
- CRC Press
- Authors
- Faraz Farooq, Alex MacKenzie, Martin Holcik
Description
While drug discovery for common disorders is somewhat standard and based on the large potential markets, the small market for most orphan diseases means that effective therapies are uncommon. With next generation DNA sequencing, the pace of inherited novel rare disease gene identification has increased markedly. Drug discovery for rare diseases is somewhat hampered by a lack of collaboration between academia and industry separating the necessary resources from skills. This volume discusses important aspects of orphan drug development such as regulatory affairs, public industry partnership, bench to bedside using examples of rare diseases, challenges of clinical trials and future directions.
Get the book
Other editions
-
- 2018-11-13
- 334 pages
- Paperback
- Woodhead Publishing
-
- 2013-11-15
- 334 pages
- Ebook
- Elsevier
-
- 1983
- 12 pages
- Paperback
- Vance Bibliographies
Similar books
-
Rare Diseases and Orphan Products: Accelerating Research and Development
By Institute of Medicine, Board on Health Sciences Policy, Committee on Accelerating Rare Diseases Research and Orphan Product DevelopmentRare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging.
-
Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases
By Jules J. BermanOften, the disease process manifested in a certain rare disease is strikingly similar to the disease process observed in a common disease. This work ties the lessons learned about rare diseases to our understanding of common ones.
-
Orphan Drugs and Rare Diseases
By David C Pryde, Michael J PalmerThis book provides an up-to-date monograph on the drug discovery and regulatory elements of therapeutics used to treat rare or "orphan" diseases.
-
Orphan Diseases and Orphan Drugs
By I. Herbert Scheinberg, J. M. WalsheOrphan Diseases and Orphan Drugs
-
Orphan Drug Law Matures into Medical Mainstay
Orphan Drug Law Matures into Medical Mainstay
-
Global Pediatric Development of Drugs, Biologics, and Medical Devices
By Jocelyn Jennings, Linda McBrideGlobal Pediatric Development of Drugs, Biologics, and Medical Devices
-
Orphan Drug Reauthorization: Hearing Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House...
By United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the EnvironmentOrphan Drug Reauthorization: Hearing Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House...
-
Searching for Magic Bullets: Orphan Drugs, Consumer Activism, and Pharmaceutical Development
By Lisa A Basara, Michael E MontagneAccording to Sidney Wolfe , a physician and well - known consumer advocate , the prevalence of doctor - bribing and acquisition of bogus clinical data through large pay - offs is higher than most people believe . Wolfe described several ...
-
Orphan Drugs
By Fred KarchOrphan Drugs
-
Food and Drug Administration's Review Process for Products to Treat Rare Diseases and Neglected Tropical Diseases: Hearing Before a Subcommittee...
By Food and Drug Administration, and Related Agencies, Rural DevelopmentFood and Drug Administration's Review Process for Products to Treat Rare Diseases and Neglected Tropical Diseases: Hearing Before a Subcommittee...